PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells

被引:35
作者
Yuki, Hiromichi [1 ]
Ueno, Shikiko [1 ]
Tatetsu, Hiro [1 ]
Niiro, Hiroaki [2 ]
Iino, Tadafumi [2 ]
Endo, Shinya [1 ]
Kawano, Yawara [1 ]
Komohara, Yoshihiro [3 ]
Takeya, Motohiro [3 ]
Hata, Hiroyuki [1 ]
Okada, Seiji [4 ]
Watanabe, Toshiki [5 ]
Akashi, Koichi [2 ]
Mitsuya, Hiroaki [1 ]
Okuno, Yutaka [1 ]
机构
[1] Kumamoto Univ Med, Dept Hematol, Kumamoto 8608556, Japan
[2] Kyushu Univ, Grad Sch Med Sci, Fukuoka 812, Japan
[3] Kumamoto Univ Med, Dept Cell Pathol, Kumamoto, Japan
[4] Kumamoto Univ, Ctr AIDS Res, Div Hematopoiesis, Kumamoto, Japan
[5] Univ Tokyo, Grad Sch Frontier Sci, Tokyo, Japan
关键词
KAPPA-B-ALPHA; TRANSCRIPTION FACTOR PU.1; REED-STERNBERG CELLS; ARTIFICIAL CHROMOSOME; REGULATORY ELEMENTS; DISTAL ELEMENTS; FINAL ANALYSIS; GENE; EXPRESSION; MUTATIONS;
D O I
10.1182/blood-2012-05-431429
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PU.1 has previously been shown to be down-regulated in classical Hodgkin lymphoma (cHL) cells via promoter methylation. We performed bisulfite sequencing and proved that the promoter region and the -17 kb upstream regulatory element of the PU.1 gene were highly methylated. To evaluate whether down-regulation of PU.1 is essential for the growth of cHL cells, we conditionally expressed PU.1 in 2 cHL cell lines, L428 and KM-H2. Overexpression of PU.1 induced complete growth arrest and apoptosis in both cell lines. Furthermore, in a Hodgkin lymphoma tumor xenograft model using L428 and KM-H2 cell lines, overexpression of PU.1 led to tumor regression or stable disease. Lentiviral transduction of PU.1 into primary cHL cells also induced apoptosis. DNA microarray analysis revealed that among genes related to cell cycle and apoptosis, p21 (CDKN1A) was highly up-regulated in L428 cells after PU.1 induction. Stable knockdown of p21 rescued PU.1-induced growth arrest in L428 cells, suggesting that the growth arrest and apoptosis observed are at least partially dependent on p21 up-regulation. These data strongly suggest that PU.1 is a potent tumor suppressor in cHL and that induction of PU.1 with demethylation agents and/or histone deacetylase inhibitors is worth exploring as a possible therapeutic option for patients with cHL. (Blood. 2013;121(6):962-970)
引用
收藏
页码:962 / 970
页数:9
相关论文
共 43 条
  • [1] [Anonymous], WHO CLASSIFICATION T
  • [2] Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma
    Barth, TFE
    Martin-Subero, JI
    Joos, S
    Menz, CK
    Hasel, C
    Mechtersheimer, G
    Parwaresch, RM
    Lichter, P
    Siebert, R
    Möller, P
    [J]. BLOOD, 2003, 101 (09) : 3681 - 3686
  • [3] Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group
    Borchmann, Peter
    Haverkamp, Heinz
    Diehl, Volker
    Cerny, Thomas
    Markova, Jana
    Ho, Anthony D.
    Eich, Hans-Theodor
    Mueller-Hermelink, Hans Konrad
    Kanz, Lothar
    Greil, Richard
    Rank, Andreas
    Paulus, Ursula
    Smardova, Lenka
    Huber, Christoph
    Doerken, Bernd
    Nerl, Christoph
    Krause, Stefan W.
    Mueller, Rolf-Peter
    Fuchs, Michael
    Engert, Andreas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) : 4234 - 4242
  • [4] Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IκBα
    Cabannes, E
    Khan, G
    Aillet, F
    Jarrett, RF
    Hay, RT
    [J]. ONCOGENE, 1999, 18 (20) : 3063 - 3070
  • [5] Long-Term Follow-Up Analysis of HD9601 Trial Comparing ABVD Versus Stanford V Versus MOPP/EBV/CAD in Patients With Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study From the Intergruppo Italiano Linfomi
    Chisesi, Teodoro
    Bellei, Monica
    Luminari, Stefano
    Montanini, Antonella
    Marcheselli, Luigi
    Levis, Alessandro
    Gobbi, Paolo
    Vitolo, Umberto
    Stelitano, Caterina
    Pavone, Vincenzo
    Merli, Francesco
    Liberati, Marina
    Baldini, Luca
    Bordonaro, Roberto
    Pesce, Emanuela Anna
    Federico, Massimo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) : 4227 - 4233
  • [6] FLOW CYTOMETRIC MEASUREMENT OF TOTAL DNA CONTENT AND INCORPORATED BROMODEOXYURIDINE
    DOLBEARE, F
    GRATZNER, H
    PALLAVICINI, MG
    GRAY, JW
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (18): : 5573 - 5577
  • [7] Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial
    Eich, Hans Theodor
    Diehl, Volker
    Goergen, Helen
    Pabst, Thomas
    Markova, Jana
    Debus, Juergen
    Ho, Anthony
    Doerken, Bernd
    Rank, Andreas
    Grosu, Anca-Ligia
    Wiegel, Thomas
    Karstens, Johann Hinrich
    Greil, Richard
    Willich, Normann
    Schmidberger, Heinz
    Doehner, Hartmut
    Borchmann, Peter
    Mueller-Hermelink, Hans-Konrad
    Mueller, Rolf-Peter
    Engert, Andreas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) : 4199 - 4206
  • [8] Overexpression of I kappa B alpha without inhibition of NF-κB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells
    Emmerich, F
    Meiser, M
    Hummel, M
    Demel, G
    Foss, HD
    Jundt, F
    Mathas, S
    Krappmann, D
    Scheidereit, C
    Stein, H
    Dorken, B
    [J]. BLOOD, 1999, 94 (09) : 3129 - 3134
  • [9] Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma
    Engert, Andreas
    Pluetschow, Annette
    Eich, Hans Theodor
    Lohri, Andreas
    Doerken, Bernd
    Borchmann, Peter
    Berger, Bernhard
    Greil, Richard
    Willborn, Kay C.
    Wilhelm, Martin
    Debus, Juergen
    Eble, Michael J.
    Soekler, Martin
    Ho, Antony
    Rank, Andreas
    Ganser, Arnold
    Truemper, Lorenz
    Bokemeyer, Carsten
    Kirchner, Hartmut
    Schubert, Joerg
    Kral, Zdenek
    Fuchs, Michael
    Mueller-Hermelink, Hans-Konrad
    Mueller, Rolf-Peter
    Diehl, Volker
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (07) : 640 - 652
  • [10] Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study
    Engert, Andreas
    Diehl, Volker
    Franklin, Jeremy
    Lohri, Andreas
    Doerken, Bernd
    Ludwig, Wolf-Dieter
    Koch, Peter
    Haenel, Mathias
    Pfreundschuh, Michael
    Wilhelm, Martin
    Truemper, Lorenz
    Aulitzky, Walter-Erich
    Bentz, Martin
    Rummel, Mathias
    Sezer, Orhan
    Mueller-Hermelink, Hans-Konrad
    Hasenclever, Dirk
    Loeffler, Markus
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) : 4548 - 4554